OBJECTIVE: Women with Marfan syndrome (MFS) and Loeys-Dietz syndrome (LDS), connective tissue disorders with genetic-predisposition for aortic dissection, have been reported to have a higher rates of preterm birth, but it is unclear whether this is due to iatrogenic or spontaneous causes. The objective of this study was to evaluate the etiology of preterm birth in a cohort of women with MFS and LDS. STUDY DESIGN: We conducted a retrospective observational cohort study of women with a clinical and genetic diagnosis of MFS or LDS who had previously been pregnant. Women were recruited through the National Marfan Foundation website and through the connective tissue clinic at Johns Hopkins Hospital. A woman's first singleton pregnancy was included. Women with incomplete information and those who delivered before 1990 were excluded. The primary outcome was the cause of preterm birth. Women who were diagnosed with MFS/LDS after their pregnancy were also compared to women who received the diagnosis prior to pregnancy in an attempt to identify how medical management changes due to disease diagnosis. RESULTS: A total of 128 pregnancies in women with MFS/LDS were included in the analysis (MFS¼104, LDS¼24). The total preterm rate in this cohort was 48% (N¼61). There was a higher rate of spontaneous preterm birth as compared to iatrogenic preterm birth (87% vs. 13%). Even among women who were not diagnosed with MFS/LDS until after their pregnancy (n¼ 35), there was a high rate of preterm birth, 45% (N¼16), and the majority was spontaneous (94%). As compared to women diagnosed after their pregnancy, those diagnosed prior to their pregnancy were more likely to deliver at an earlier gestational age (36.8 vs. 38.4 weeks, p<0.001), receive general anesthesia (14% vs 3%, p<0.001) and have a cesarean delivery (54% vs 20%, p<0.001). The primary reason for 80% of the cesarean deliveries in the group diagnosed prior to pregnancy was listed as connective tissue disorder. CONCLUSION: In agreement with previous literature, this study highlights that women with MFS and LDS are at higher risk for preterm birth. This risk appears to be driven by spontaneous rather than iatrogenic preterm birth. 
OBJECTIVE:
The fetal fraction of circulating cell-free DNA (cfDNA) is placental in origin, and is a critical variable in noninvasive prenatal testing (NIPT). Although fetal cfDNA is known to be hypomethylated relative to maternal cfDNA, the methylation profile of circulating cfDNA in maternal plasma has not been well studied. We sought to determine whether hypomethylated cfDNA in maternal plasma: (i) could serve as a proxy for fetal fraction and (ii) was reduced in maternal obesity, as the fetal fraction of circulating cfDNA is known to be decreased in the setting of maternal obesity. STUDY DESIGN: In this prospective pilot study, maternal plasma was collected at admission and 24-48h postpartum (PP) from women admitted for delivery at term. Subjects were enrolled into 4 groups: lean (pre-pregnancy BMI <25 kg/m 2 ) no labor (Lean-NL) (n¼15); lean labor (Lean-L) (n¼18); obese (pre-pregnancy BMI !30 kg/m 2 ) no labor (OB-NL) (n¼16); and obese labor (OB-L) (n¼11). Total cfDNA was isolated and genome-wide methylation levels determined using 0.2x coverage whole-genome bisulfite sequencing (WGBS) in all 60 antepartum (AP) samples and in matching PP samples in w5 patients per study group. Calibration was performed using serial dilutions of fully methylated and unmethylated DNA. RESULTS: Hypomethylated cfDNA fraction was significantly lower in OB vs lean pregnant women (27.0 AE0.5% vs 28.5AE0.3%, p¼0.008). Hypomethylated fraction was significantly higher in AP vs PP samples overall, and when stratified by BMI (Fig 1A/B) , demonstrating that the placenta contributes to hypomethylated cfDNA in maternal circulation. However, matched analyses of hypomethylation before and after delivery demonstrated a relatively small contribution of placental cfDNA to the overall hypomethylated fraction, w15%. CONCLUSION: The lower hypomethylated cfDNA fraction in OB patients is consistent with our prior observation of reduced placental cfDNA release in a mouse model of diet-induced obesity. Contrary to expectations, the placenta accounted for a relatively low proportion of all hypomethylated cfDNA in maternal plasma at term, suggesting that hypomethylation is not a good proxy for the fetal fraction. The finding of 20-25% hypomethylated cfDNA in nonpregnant healthy women is consistent with the oncology literature. Understanding the impact of pregnancy and maternal obesity on the methylation profile of cfDNA may have broader implications for NIPT, as well as for oncology researchers.
910 Abnormal chorionic villi morphology and risk of aneuploidy Nasim C. Sobhani, Arianna G. Cassidy, Zhongxia Qi, Jingwei Yu, Mary E. Norton, Shilpa Chetty University of California, San Francisco, San Francisco, CA OBJECTIVE: To evaluate the association between chorionic villi morphology and aneuploidy on chorionic villus sampling (CVS), using a simple morphologic scoring system. STUDY DESIGN: This was a retrospective cohort study of singleton pregnancies that underwent CVS at a single institution from 2006 to 2017. A simple scoring method was utilized to evaluate each specimen with regards to number of buds, branches, and veins. These budding, branching, and vascularity scores ranged from 0 to 3, with 0 indicating the absence of the structure, 1 indicating presence in < 25% of the sample, 2 indicating presence in 25-75% of the sample, and 3 indicating presence in > 75% of the sample. A composite score was calculated as a sum of the individual scores. Based on the distribution of scores in this cohort, individual scores were recategorized into normal (1-2) and abnormal (0 or 3), and the composite score was re-categorized into normal (3-6) and abnormal (0-2 or 7-9). The primary predictors were abnormal budding, branching, vascularity, and composites scores, while the primary outcome was presence of aneuploidy on cytogenetics. Fisher's exact test compared proportions between categorical groups, and logistic regression generated odds ratios.
RESULTS: A total of 1,175 CVS specimens met criteria for inclusion, with 30.6% demonstrating aneuploidy. There was no statistically significant difference in rate of abnormal budding score between the two groups (2.2% aneuploid vs 2.5% euploid, p ¼ 0.81). The difference in rate of abnormal branching score approached but did not reach statistical significance (5.0% aneuploid vs 2.8%, euploid p ¼ 0.06). There was a statistically significant difference in rate of abnormal vascularity score (5.0% aneuploid vs 1.8% euploid, p ¼ 0.002, OR 2.8, 95% CI 1.4-5.6) and in rate of abnormal composite score (7.2% aneuploid vs 3.8% euploid, p ¼ 0.012, OR 2.0, 95% CI 1.2-3.4) between the two groups. CONCLUSION: We found that an abnormal composite morphologic score was associated with aneuploidy on CVS specimens. While other studies have demonstrated an association between aneuploidy and complex aspects of chorionic villus histomorphology, this scoring system is simple, rapid, and easy for clinical cytogeneticists to perform at the time of routine diagnosis. Future studies should evaluate the potential association between abnormal morphologic scores and placentally-mediated adverse pregnancy outcomes, such as hypertensive disorders and fetal growth restriction.
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